"CEO Peter Cook First, we’ll be very carefully monitoring Relenza royalties each quarter and informing our shareholders about that. Second, with laninamavir we’d expect to see progress towards a rest-of-the-world partner and also to see progress toward the commercial introduction of the product in Japan, including the NDA submission and commencement of the prophylaxis study. Additionally, we’ll see progress on the clinical studies of laninamivir underway in the West. Third, we’d expect to see progress on the licensing of the HRV program and fourth we’d expect progress around the Hepatitis C program we’ve licensed to Boehringer Ingelheim, which we’ve not had a lot to say about in the recent period. In addition, we’ve spent a considerable amount of time on strategy in the last few months and we’ve identified that as quickly as possible we want to be in the position of having two or three products out in the market generating royalties at any one point in time. That’s going to require the addition of appropriate programs to our portfolio. corporatefile."
